Faculty Summaries
Matthew Robinson, PhD
Matthew Robinson, PhD
Assistant Professor
Matthew.Robinson@fccc.edu
Office Phone: 215-728-3141
Fax: 215-728-2741
Office: W363

Original Articles

  • Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment. Clin Cancer Res. 2011 March 15, 2011;17(6):1509-20.
  • Reddy S, Robinson MK. Immuno-Positron Emission Tomography in Cancer Models. Semin Nucl Med. 2010 May 40:182-189. Epub 2010 Mar 31. PubMed
  • Robinson MK, Alpaugh RK, Borghaei H. Naptumomab estafenatox: a new immunoconjugate. Expt Opin Biol Ther. 2010 Feb 10(2):273-279. Epub 2010 Jan 8. PubMed
  • Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, Simmons HH, von Mehren M, Shchaveleva I, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific-single chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4;99(9):1415-25. Epub 2008 Oct 7. PubMed
  • Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the a-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin. Cancer Res. 2008 Feb 1;14(3):875-82. Epub 2008 Feb 5. PubMed
  • Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams, GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol. Immunotherapy. 2008 Mar;57(3):367-378. Epub 2007 Aug 4.PubMed
  • Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.J. Immunol. 2007 Sep 1;179(5):2815-23. PubMed
  • Yuan QA, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol. Cancer Ther. 2006;5:2096-2105. PubMed
  • Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother. Radiopharm. 2005;20:603-613
  • Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15;65(4):1471-8.
Top